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Background: The Swiss label of oral fingolimod (0.5 mg once daily) requires a 6-hour first dose observation (FDO)
including an ECG prior to and 6 hours after the first intake but in comparison to other countries such as Austria,
Australia and Canada there are no restrictions regarding the clinical settings of the FDO procedure in Switzerland.
We present here our real-world experience of the 6 hour FDO procedure in three different clinical settings, following
fingolimod treatment initiation. This is the first report on the FDO of fingolimod in these real-world clinical settings in
Swiss patients with multiple sclerosis (MS).
Methods: This was a retrospective, multi-clinic, observational study of 136 patients with relapsing-remitting multiple
sclerosis. Summary statistics have been used to present the data.
Results: Only two patients (<1.5% [2/136]) experienced symptoms after the first dose of fingolimod. Atrioventricular
conduction abnormalities were reported in 3% (4/136) of patients, which resolved spontaneously within 24 hours of
treatment initiation. During the average 6.8 months follow-up, 96% (131/136) of the patients remained on therapy
Conclusions: These findings support the safety and feasibility of FDO and tolerability of fingolimod in real-world clinical
settings.
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Fingolimod 0.5 mg once-daily (FTY720; Gilenya™, Novartis
Pharma AG, Basel, Switzerland), a sphingosine 1-phosphate
(S1P) receptor modulator, is the first oral therapy approved
by the Swiss Regulatory Agency for treating patients with
relapsing-remitting multiple sclerosis (RRMS) to reduce the
frequency of relapses and delay disability progression [1].
Various pharmacodynamics effects of fingolimod are mani-
fested as a consequence of the fingolimod mechanism of
action of S1P receptor modulation since these receptors are
ubiquitously distributed across different tissues [2]. Fingoli-
mod initiation is associated with a transient reduction in
heart rate and possible disturbances in atrioventricular
(AV) conduction within the first few hours after first intake
[3-5]. Hence, already at the time of market authorization in
January 2011, the Swiss label of fingolimod made it a* Correspondence: mc@neurozentrumbellevue.ch
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unless otherwise stated.mandate to perform an ECG prior to and after 6 hours of
the first dose administration, and recommended regular
monitoring of blood pressure and pulse (first dose observa-
tion, FDO), which is similar to the current recommenda-
tions of other international health authorities. Here, we
report for the first time the real-world experience of fingoli-
mod treatment initiation and 6 hours FDO procedure in
three different clinical settings outside of University Hospi-
tals (MS centre, day clinic, private practice) since there are
no restrictions on location of the FDO procedure in
Switzerland.Methods
Data were collected retrospectively from the charts of
RRMS patients treated and monitored as required by the
Swiss label for fingolimod between August 2011 and
May 2012 at three different locations (i.e. it did not en-
compass the new recommendations regarding the obser-
vation of patients with pre-existing cardiac conditions,al. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Ramseier et al. BMC Pharmacology and Toxicology  (2015) 16:7 Page 2 of 4published by the Swiss Regulatory Agency in October
2012 [1]). Site 1 was the MS centre, Cantonal Hospital
Aarau, Aarau (n = 58), site 2 was the Clinique de Car-
ouge in Carouge (office-based neurologist using a day
clinic for FDO, n = 17) and site 3 was the Neurocentre
Bellevue in Zurich, an office-based neurologist perform-
ing the FDO in his practice (n = 61). Prior to the FDO
appointment all patients received essential information
on fingolimod from their treating physician. They were
informed about the potential side effects of fingolimod
(short and long term), about the FDO procedure, includ-
ing the reasons for ECG and the 6 h observation. Infor-
mation was also provided on the required follow-up
examinations after FDO over the next few months, in-
cluding blood analysis and ophthalmological examin-
ation required by the Swiss label. Patients received
recommendations on taking tablets including explan-
ation of tablet packaging and drug description. The Can-
tonal Ethics Committee Zurich waived the review of this
study as the data were obtained from retrospective chartFigure 1 Overview of the FDO process in the three different clinical s
number of days prior to FDO; *Depends on site, usually internist, cardiologreviews, and the information was recorded by the investi-
gator in such manner that subjects cannot be identified,
directly or through identifiers linked to the subjects.
Results and discussion
Overview of FDO process and associated workload
FDO measurements were performed in the daily clinical
setting, which involved an ECG at the beginning and at
the end of 6 hours and hourly recording of vital parame-
ters (blood pressure and heart rate) (Figure 1). Between
active FDO assessments, performed by the nurse or the
physician, patients entertained themselves with activities
such as reading, using their personal laptop, lunching to-
gether or discussing health related aspects of MS. A
nurse took care of up to 2 patients using a single ECG
device. She spent two times ten minutes to apply and
record the ECG (prior to and 6 hours after the first in-
take), as well as five times 2 minutes to measure the vital
parameters, representing a total workload of 30 minutes
for the nurse over the 6 hour period. Interpretation ofettings. Not for Neurocentre Bellevue. ECG recording was performed a
ist or neurologist; **Nurse or MS nurse; VP, vital parameters.








Total number of patients undergoing FDO 58 17 61 136
Patients with no FDO events (n) 57 16 57 130
Patients discharged at 6 hours (n) 57 16 59 132
Patients requiring extended observation after 6 hours (n) 1a 0 0 1
Patients requiring observation on 2nd day (n) 0 1b 2c 3
Symptomatic patients (n) 0 0 2d 2
Patients with ECG Abnormalities (n) 1a 1b 2c 4
1st degree AV Block (n) 0 0 2c 2
2nd degree AV Block Type I (Wenkebach) (n) 1a 1b 0 2
2nd degree AV Block Type II (Mobitz Type II) (n) 0 0 0 0
Symptomatic events that resolved by the end of 6 h observation (n) 0 0 2d 2
ECG events that had resolved at extended observation or follow-up examination on
the 2nd day (n)
1a 1b 2c 4
a2nd degree AV block, Wenkebach type: extension of observation by 1 h and repeat of ECG; AV block had resolved.
b2nd degree AV block, Wenkebach type: 24 h Holter ECG as a precautionary measure; AV block had resolved and no further finding observed on Holter ECG.
c1st degree AV blocks: patients were asked to return to the practice the next day for a single ECG; AV block had resolved.
d1 patient with vertigo-like sensation, 1 patient with palpitations (HR in normal range 74 bpm): symptoms had resolved for both patients by the end of the
6 h observation.
AV, atrioventricular; HR, heart rate; bpm, beats per minute.
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workload of 10 minutes altogether (two times five minutes
for each ECG). The procedures upon appearance of ECG
abnormalities or symptoms after 6 hours varied in the differ-
ent clinical settings (see Figure 1). If, as stated in the Swiss
label, heart rate dropped below 40 bpm during 6 hours
FDO, another observation period of 6 hours (including ECG
prior to and 6 hours after fingolimod administration) had to
be performed on the second day of treatment.
Real-world FDO outcomes in the three centres
Data was collected from 136 RRMS patients. 33 were treat-
ment naïve and 103 were previously treated with interferon
beta, glatiramer acetate or natalizumab. In total, 130
(95.5%) patients had uneventful FDO, 6 patients experi-
enced cardiac events associated with the first dose (Table 1).
Four patients had an AV block: 2 first-degree AV blocks
and 2 second-degree AV blocks of Type Mobitz I. All the
AV blocks detected resolved spontaneously within 24 hours.
This was ensured either by monitoring with Holter ECG or
an on-site ECG the following day. Two patients reported
symptomatic events that resolved spontaneously without
any pharmacological intervention (1 patient with vertigo-
like sensation, 1 patient with palpitations [HR in normal
range, 74 bpm]). The average duration of follow up was
6.8 months, and 131 (96%) of patients remained on therapy.
Conclusions
The FDO experience reported here indicates that fingoli-
mod is generally well tolerated upon treatment initiation.
The majority of patients had no cardiac events during theFDO. Although symptomatic events were rare, the detec-
tion of 1st and 2nd degree Mobitz Type I AV blocks,
which in some instances can have clinical implications,
highlights the importance of monitoring the patients at
treatment initiation and emphasizes the need for compre-
hensive information beforehand. All 3 participating sites
capably facilitated the FDO procedure. Our data, which
are in line with the phase 3 trial data [3,4] and other FDO
related real-world observational studies [6,7], show that
despite strict FDO guidelines in Switzerland, initiation of
fingolimod therapy can also take place in clinical settings
(MS centre, day clinic, private practice) outside of Univer-
sity Hospitals with a reasonable workload. They also sup-
port the safety and feasibility of FDO as well as the good
tolerability profile of fingolimod in these real-world clin-
ical settings, as shown by rates of adverse events and
drop-outs comparable to those published previously [3,4],
supporting the fact that fingolimod can safely be used in
MS centres, day clinics and private practices.Abbreviations
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